232 related articles for article (PubMed ID: 28358430)
1. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Bredemeier M; Kasimir-Bauer S; Kolberg HC; Herold T; Synoracki S; Hauch S; Edimiris P; Bankfalvi A; Tewes M; Kimmig R; Aktas B
Mol Med Rep; 2017 May; 15(5):2957-2968. PubMed ID: 28358430
[TBL] [Abstract][Full Text] [Related]
2. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843
[TBL] [Abstract][Full Text] [Related]
6. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
[TBL] [Abstract][Full Text] [Related]
7. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
[TBL] [Abstract][Full Text] [Related]
9. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
10. Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.
Todenhöfer T; Hennenlotter J; Dorner N; Kühs U; Aufderklamm S; Rausch S; Bier S; Mischinger J; Schellbach D; Hauch S; Feniuk N; Bedke J; Gakis G; Stenzl A; Schwentner C
J Cancer Res Clin Oncol; 2016 May; 142(5):1013-20. PubMed ID: 26910601
[TBL] [Abstract][Full Text] [Related]
11. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters.
Li J; Zhou BP
BMC Cancer; 2011 Feb; 11():49. PubMed ID: 21284870
[TBL] [Abstract][Full Text] [Related]
12. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
Aktas B; Tewes M; Fehm T; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R46. PubMed ID: 19589136
[TBL] [Abstract][Full Text] [Related]
13. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
Chebouti I; Kasimir-Bauer S; Buderath P; Wimberger P; Hauch S; Kimmig R; Kuhlmann JD
Oncotarget; 2017 Jul; 8(30):48820-48831. PubMed ID: 28415744
[TBL] [Abstract][Full Text] [Related]
14. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
15. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
[TBL] [Abstract][Full Text] [Related]
16. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis.
Barrière G; Riouallon A; Renaudie J; Tartary M; Rigaud M
BMC Cancer; 2012 Mar; 12():114. PubMed ID: 22443102
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
19. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.
Bock C; Rack B; Huober J; Andergassen U; Jeschke U; Doisneau-Sixou S
Future Oncol; 2014 Aug; 10(10):1751-65. PubMed ID: 25303055
[TBL] [Abstract][Full Text] [Related]
20. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
